Drugs / L-Phenylalanine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Maapliv | — | 2025-07-28 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06433310 | Oct 2024 → Dec 2027 expected | — | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01208324 Comparator | Mar 2010 → Nov 2018 | premature menopause | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Phenylalanine | “L-Phenylalanine (6.6 g)” NCT01208324 ↗ |
| Route | Oral | “Each test day will involve the ingestion of 70 capsules.” NCT01208324 ↗ |